Zvarik M, Martinicky D, Hunakova L, Sikurova L
Department of Nuclear Physics and Biophysics, Faculty of Mathematics, Physics and Computer Science, Comenius University, Bratislava, Slovakia.
Department of Gynecological Oncology, National Cancer Institute, Bratislava, Slovakia.
J Photochem Photobiol B. 2015 Dec;153:191-7. doi: 10.1016/j.jphotobiol.2015.09.019. Epub 2015 Sep 24.
Pteridines belong to a class of fluorescent metabolites that are excreted by humans in urine and their concentrations can reflect various pathophysiological states. We quantified the differences in urinary pteridine levels in patients with malignant and benign ovarian tumors and in healthy individuals. Urine samples were centrifuged and supernatants were oxidized by MnO2 before analysis. Levels of neopterin, biopterin, and pterin were assessed by fluorescence analysis of human urine after HPLC separation. We have revealed that the median neopterin levels were higher in urine samples from patients with malignant (0.226 μmol/mmol creatinine) and benign ovarian tumors (0.150 μmol/mmol creatinine) than in healthy subjects (0.056 μmol/mmol creatinine). The median neopterin levels of patients with malignant tumors were higher (1.5-times) than in patients with benign tumors. The median biopterin level in urine of patients with benign ovarian tumors (0.268 μmol/mmol creatinine) was found to be very close to the level in patients with malignant ovarian tumors (0.239 μmol/mmol creatinine), and both were higher than in healthy samples (0.096 μmol/mmol creatinine). The levels of urine pterin followed a pattern similar to neopterin levels for both ovarian tumors, but their concentrations were about three times lower than neopterin levels.
蝶啶属于一类荧光代谢产物，可由人体经尿液排出，其浓度能够反映各种病理生理状态。我们对患有恶性和良性卵巢肿瘤的患者以及健康个体尿液中蝶啶水平的差异进行了量化。尿液样本经离心处理，上清液在分析前用二氧化锰进行氧化。新蝶呤、生物蝶呤和蝶呤的水平通过高效液相色谱分离后人尿的荧光分析来评估。我们发现，恶性卵巢肿瘤患者（0.226μmol/mmol肌酐）和良性卵巢肿瘤患者（0.150μmol/mmol肌酐）尿液样本中的新蝶呤中位数水平高于健康受试者（0.056μmol/mmol肌酐）。恶性肿瘤患者的新蝶呤中位数水平比良性肿瘤患者高（1.5倍）。发现良性卵巢肿瘤患者尿液中的生物蝶呤中位数水平（0.268μmol/mmol肌酐）与恶性卵巢肿瘤患者的水平（0.239μmol/mmol肌酐）非常接近，且两者均高于健康样本（0.096μmol/mmol肌酐）。两种卵巢肿瘤患者尿液中蝶呤的水平呈现出与新蝶呤水平相似的模式，但其浓度比新蝶呤水平低约三倍。
